Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-30

Karyopharm Therapeutics (KPTI)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,320,902
Richard Paulson total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
87.84%
Say-on-pay support, latest vote
Companies that benchmark against KPTI
12 companies name KPTI as a compensation peer

Each company listed discloses KPTI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named KPTI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Richard Paulson$770,000$100,100$838,996$241,544$350,350$0$19,912$2,320,902
President and Chief Executive Officer
Reshma Rangwala567,7361,051,09679,492120,766178,837018,2072,016,134
Executive Vice President, Chief Medical Officer and Head of Research
Stuart Poulton500,135295,012312,293115,736157,543018,8611,399,580
Executive Vice President, Chief Development Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Richard Paulson$2,320,902$2,069,341$2,626,288+251,561
Reshma Rangwala2,016,1341,124,4441,227,789+891,690
Stuart Poulton1,399,580

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Reshma RangwalaEVP & Chief Medical Officer2026-04-21D449$9$4,014CommonForm 4 ↗
Reshma RangwalaEVP & Chief Medical Officer2026-05-13D408103,876CommonForm 4 ↗
Michael ManoEVP, CLO&Secretary2026-05-13A70000CommonForm 4 ↗
Michael ManoEVP, CLO&Secretary2026-05-13D266102,527CommonForm 4 ↗
Kristin AbateChief Accounting Officer2026-05-13A12100CommonForm 4 ↗
Reshma RangwalaEVP & Chief Medical Officer2026-05-13A94700CommonForm 4 ↗
Sohanya Roshan ChengEVP & Chief Commercial Officer2026-05-13A94700CommonForm 4 ↗
Sohanya Roshan ChengEVP & Chief Commercial Officer2026-05-13D324103,078CommonForm 4 ↗
Kristin AbateChief Accounting Officer2026-05-13D5310504CommonForm 4 ↗
Richard PaulsonDirector2026-05-13A4,92000CommonForm 4 ↗
Stuart PoultonEVP, Chief Development Officer2026-05-13D403103,829CommonForm 4 ↗
Richard PaulsonDirector2026-05-13D2,2031020,929CommonForm 4 ↗
Stuart PoultonEVP, Chief Development Officer2026-05-13A89600CommonForm 4 ↗
Barry E. GreeneDirector2026-05-21A15,50800CommonForm 4 ↗
Zhen SuDirector2026-05-21A15,50800CommonForm 4 ↗
Garen G. BohlinDirector2026-05-21A15,50800CommonForm 4 ↗
Chen SchorDirector2026-05-21A15,50800CommonForm 4 ↗
Christy J. OligerDirector2026-05-21A15,50800CommonForm 4 ↗
Deepika PakianathanDirector2026-05-21A15,50800CommonForm 4 ↗
Stuart PoultonEVP, Chief Development Officer2026-07-28D18971,342CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Richard PaulsonRSU5,600$41,216
Richard PaulsonRSU4,81235,416
Richard PaulsonPSU5,60041,216
Reshma RangwalaRSU8,84265,077
Reshma RangwalaRSU4,58333,731
Richard PaulsonRSU20,000147,200
Richard PaulsonPSU14,760108,634
Richard PaulsonOption40,0007.95
Reshma RangwalaOption9,1667.95
Richard PaulsonRSU114,285841,138
Reshma RangwalaPSU2,84220,917
Reshma RangwalaPSU1,88913,903
Reshma RangwalaRSU5,41639,862
Richard PaulsonOption999154.95
Reshma RangwalaRSU1,0837,971
Reshma RangwalaOption55691.5
Reshma RangwalaOption10,8337.95
Richard PaulsonRSU19,680144,845
Reshma RangwalaRSU2,22216,354
05

Incentive-plan design — the Compensation Discussion & Analysis

The objective of our executive compensation program is to align management interests with the drivers of value creation for our stockholders and support the achievement of our strategic goals and objectives. We are committed to our compensation philosophy, which has historically incorporated the following principles: Pay for Performance. We seek to provide competitive compensation opportunities to attract, retain and motivate executive talent. Reward Performance. We promote the achievement of key strategic and financial performance measures by linking short-term and long-term cash and equity incentives to the achievement of measurable corporate performance goals.

CEO STI target (% of salary)65%
CEO LTI target (% of salary)
Independent consultantAlpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2110,025,1981,388,27417,21387.84%Passed
20252025-05-282,716,9511,041,611296,61172.29%Passed
20242024-05-2955,719,91712,055,04465,93082.21%Passed
20232023-05-2464,822,47517,787,485275,73878.47%Passed
20222022-05-1947,288,4396,790,078230,06587.44%Passed
20212021-05-2137,981,9622,969,679122,93692.75%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2187.84%a
20252025-05-2872.29%b
20242024-05-2982.21%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Barry E. GreeneIndependent · Lead Independent Director · Compensation · Nominating, Corporate Governance & Compliance (Chair)$115,000$0$15,142$130,142
Mansoor Raza Mirza, M.DIndependent · Commercialization and Portfolio · Departed during FY41,413015,14260,000116,555
Deepika R. Pakianathan, Ph.DIndependent · Audit · Compensation (Chair) · Commercialization and Portfolio90,000015,142105,142
Christy J. OligerIndependent · Compensation · Commercialization and Portfolio (Chair)80,000015,14295,142
Garen G. BohlinIndependent · Audit (Chair) · Compensation80,000015,14295,142
Chen Schor, M.B.A., C.P.AIndependent · Audit · Nominating, Corporate Governance & Compliance70,000015,14285,142
Zhen Su, M.D., M.B.AIndependent · Commercialization and Portfolio60,000015,14275,142
Richard Paulson, M.B.AEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 20,000 / 20,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$536,413
Equity awards (grant-date value)$0
All other compensation$60,000
Total cost of the board$596,413

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Karyopharm Therapeutics2025Richard Paulson$770,000$838,996$241,544$350,350$2,320,902

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Richard PaulsonDEF 14A2026-04-130001503802-26-000023Section “025 Summary Compensation Table” · page 61. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348
2Section 01, Reshma RangwalaDEF 14A2026-04-130001503802-26-000023Section “025 Summary Compensation Table” · page 61. As printed: 2,016,134. Filing ↗machine: r6 · c29 · span 1235945–1235954
3Section 01, Stuart PoultonDEF 14A2026-04-130001503802-26-000023Section “025 Summary Compensation Table” · page 61. As printed: 1,399,580. Filing ↗machine: r4 · c29 · span 1214141–1214150
4Section 07, pay ratio10-K2026-02-130001193125-26-049397Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 08, Barry E. GreeneDEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 130,142. Filing ↗machine: t8 · r3 · c16 · span 456073–456080
6Section 08, Mansoor Raza Mirza, M.DDEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 116,555. Filing ↗machine: t8 · r4 · c16 · span 462444–462451
7Section 08, Deepika R. Pakianathan, Ph.DDEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 105,142. Filing ↗machine: t8 · r6 · c16 · span 475163–475170
8Section 08, Christy J. OligerDEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 95,142. Filing ↗machine: t8 · r5 · c16 · span 468798–468804
9Section 08, Garen G. BohlinDEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 95,142. Filing ↗machine: t8 · r2 · c16 · span 449721–449727
10Section 08, Chen Schor, M.B.A., C.P.ADEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 85,142. Filing ↗machine: t8 · r7 · c16 · span 481527–481533
11Section 08, Zhen Su, M.D., M.B.ADEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 75,142. Filing ↗machine: t8 · r8 · c16 · span 487885–487891
12Section 08, Richard Paulson, M.B.ADEF 14A2026-04-130001503802-26-000023Section “Director Compensation”. As printed: 0. Filing ↗
13Section 02, Reshma Rangwala 2026-04-21Form 42026-04-220001825322-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Reshma Rangwala 2026-05-13Form 42026-05-150001193125-26-226685Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Michael Mano 2026-05-13Form 42026-05-150001193125-26-226604Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Michael Mano 2026-05-13Form 42026-05-150001193125-26-226604Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Kristin Abate 2026-05-13Form 42026-05-150001193125-26-226616Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Reshma Rangwala 2026-05-13Form 42026-05-150001193125-26-226685Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Sohanya Roshan Cheng 2026-05-13Form 42026-05-150001193125-26-226652Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Sohanya Roshan Cheng 2026-05-13Form 42026-05-150001193125-26-226652Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Kristin Abate 2026-05-13Form 42026-05-150001193125-26-226616Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Richard Paulson 2026-05-13Form 42026-05-150001193125-26-226613Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Stuart Poulton 2026-05-13Form 42026-05-150001193125-26-226697Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Richard Paulson 2026-05-13Form 42026-05-150001193125-26-226613Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Stuart Poulton 2026-05-13Form 42026-05-150001193125-26-226697Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Barry E. Greene 2026-05-21Form 42026-05-260001291963-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Zhen Su 2026-05-21Form 42026-05-260001991642-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Garen G. Bohlin 2026-05-21Form 42026-05-260001254705-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Chen Schor 2026-05-21Form 42026-05-260001340875-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Christy J. Oliger 2026-05-21Form 42026-05-260001822092-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Deepika Pakianathan 2026-05-21Form 42026-05-260001270734-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Stuart Poulton 2026-07-28Form 42026-07-300001193125-26-326290Insider equity transaction reported since the proxy statement. Filing ↗
33Section 06, 2026 voteForm 8-K2026-05-280001503802-26-000027Item 5.07 · say-on-pay result. As reported: 87.84% (votes for as printed: 10,025,198). Filing ↗
34Section 06, 2025 voteForm 8-K2025-05-290000950170-25-079009Item 5.07 · say-on-pay result. As reported: 72.29% (votes for as printed: 2,716,951). Filing ↗
35Section 06, 2024 voteForm 8-K2024-05-310001193125-24-151049Item 5.07 · say-on-pay result. As reported: 82.21% (votes for as printed: 55,719,917). Filing ↗
36Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
37Section 09b board cost (computed)ComputedcomputedCash 536,413 + equity 0 + all other 60,000 = 596,413, summed across the director compensation table rows.machine: formula: Σ = 596,413
38Karyopharm Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-130001503802-26-000023CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348